<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692379</url>
  </required_header>
  <id_info>
    <org_study_id>REVASCAT</org_study_id>
    <nct_id>NCT01692379</nct_id>
  </id_info>
  <brief_title>Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours</brief_title>
  <acronym>REVASCAT</acronym>
  <official_title>RandomizEd Trial of reVascularizAtion With Solitaire FR® Device Versus Best mediCal Therapy in the Treatment of Acute Stroke Due to anTerior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Ictus Malaltia Vascular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Ictus Malaltia Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the hypothesis that mechanical embolectomy with the Solitaire FR device is&#xD;
      superior to medical management alone in achieving favorable outcome in the distribution of&#xD;
      the modified Rankin Scale scores at 90 days in subjects presenting with acute large vessel&#xD;
      ischemic stroke &lt; 8 hours from symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, randomized, controlled, open, blinded-endpoint trial with a&#xD;
      sequential design. The randomization employs a 1:1 ratio of mechanical embolectomy with the&#xD;
      CE MARK approved stentriever Solitaire FR® versus medical management alone. Randomization&#xD;
      will be done under a minimization process using age, baseline NIHSS, therapeutic window and&#xD;
      vessel occlusion site. For the primary endpoint, subjects will be followed for 90 days&#xD;
      post-randomization.&#xD;
&#xD;
      Interim analysis will be performed as preplanned and interpreted by the Data Safety&#xD;
      Monitoring Board (DSMB) after the first 174, 346 and 518 patients representing 25%, 50% and&#xD;
      75% of the planned sample size have completed their 90-day follow-up. The DSMB will advise&#xD;
      the executive committee (EC) on recommendations to stop the trial early either for reasons of&#xD;
      safety, efficacy, futility or to adjust the sample size. The latter may be necessary as given&#xD;
      the paucity of data regarding natural history of the non-treated patients assumptions&#xD;
      regarding rates of favorable outcomes in this group of patients may be incorrect. Of note,&#xD;
      sample size adjustment based on different than expected outcomes rates is permitted, but it&#xD;
      is not permitted to adjust the sample size based on change in the pre-specified treatment&#xD;
      effect which is set at 10%.&#xD;
&#xD;
      Subject population: Subjects presenting with acute ischemic stroke within 8 hours from&#xD;
      symptom onset and whose strokes are attributable to an occlusion of the internal carotid or&#xD;
      proximal MCA (M1) arteries. Subjects are either ineligible for IV alteplase or have received&#xD;
      IV alteplase therapy without recanalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following DSMB advice after first interim analysis (n=174)&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between-group comparison of the distribution of the modified Rankin Scale scores (shift analysis)</measure>
    <time_frame>90 days after enrollment</time_frame>
    <description>evaluated by two separate assessors who are blinded to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 90 days</measure>
    <time_frame>90 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracerebral Hemorrhage</measure>
    <time_frame>24h (-2/+12 hours) after enrollment</time_frame>
    <description>Deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans evaluated by independent CT/MR Core Lab and Clinical Events Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct Volume</measure>
    <time_frame>24h (-2/+12h) post treatment</time_frame>
    <description>Infarct volume evaluated in a second neuroimaging after treatment evaluated by independent CT/MR Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel recanalization</measure>
    <time_frame>24h post treatment</time_frame>
    <description>Vessel recanalization evaluated by CT angiography or MRA at 24 hours in both treatment groups evaluated by independent CT/MR Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraprocedural related complications in endovascular arm</measure>
    <time_frame>During endovascular treatment</time_frame>
    <description>Procedural related complications in the endovascular treatment arm: arterial perforation, arterial dissection, and embolization in a previously uninvolved vascular territory evaluated by the Angiography Core Lab and the Clinical Events Committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>Endovascular treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical embolectomy with Solitaire FR device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solitaire FR device</intervention_name>
    <description>Mechanical embolectomy in anterior large vessel occlusion</description>
    <arm_group_label>Endovascular treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical treatment</intervention_name>
    <description>Standard of care in acute ischemic stroke including intravenous rTPA</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment or&#xD;
             the treatment is contraindicated (e.g., subject presents beyond recommended time from&#xD;
             symptom onset), or where patient has received IV thrombolytic therapy without&#xD;
             recanalization after a minimum of 30 min from start of iv tPA infusion&#xD;
&#xD;
          -  2. No significant pre-stroke functional disability (mRS ≤ 1)&#xD;
&#xD;
          -  3. Baseline NIHSS score obtained prior to randomization must be equal or higher than 6&#xD;
             points&#xD;
&#xD;
          -  4. Age ≥18 and ≤ 85.&#xD;
&#xD;
          -  5. Occlusion (TICI 0-1) of the intracranial ICA (distal ICA or T occlusions), MCA-M1&#xD;
             segment or tandem proximal ICA/MCA-M1 suitable for endovascular treatment, as&#xD;
             evidenced by CTA, MRA or angiogram, with or without concomitant cervical carotid&#xD;
             occlusion or stenosis&#xD;
&#xD;
          -  6. Patient treatable within eight hours of symptom onset. Symptoms onset is defined as&#xD;
             point in time the patient was last seen well (at baseline). Treatment start is defined&#xD;
             as groin puncture.&#xD;
&#xD;
          -  7. Informed consent obtained from patient or acceptable patient surrogate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical criteria&#xD;
&#xD;
          -  1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant&#xD;
             therapy with INR &gt; 3.0&#xD;
&#xD;
          -  2. Baseline platelet count &lt; 30.000/µL&#xD;
&#xD;
          -  3. Baseline blood glucose of &lt; 50mg/dL or &gt;400mg/dl&#xD;
&#xD;
          -  4. Severe, sustained hypertension (SBP &gt; 185 mm Hg or DBP &gt; 110 mm Hg)&#xD;
&#xD;
          -  5. Patients in coma (NIHSS item of consciousness &gt;1) (Intubated patients for transfer&#xD;
             could be randomized only in case an NIHSS is obtained by a neurologist prior&#xD;
             transportation).&#xD;
&#xD;
          -  6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS&#xD;
&#xD;
          -  7. Serious, advanced, or terminal illness with anticipated life expectancy of less&#xD;
             than one year.&#xD;
&#xD;
          -  8. History of life threatening allergy (more than rash) to contrast medium&#xD;
&#xD;
          -  9. Subjects who has received iv t-PA treatment beyond 4,5 hours from the beginning of&#xD;
             the symptoms&#xD;
&#xD;
          -  10. Renal insufficiency with creatinine ≥ 3 mg/dl&#xD;
&#xD;
          -  11. Woman of childbearing potential who is known to be pregnant or lactating or who&#xD;
             has a positive pregnancy test on admission.&#xD;
&#xD;
          -  12. Subject participating in a study involving an investigational drug or device that&#xD;
             would impact this study.&#xD;
&#xD;
          -  13. Cerebral vasculitis&#xD;
&#xD;
          -  14. Patients with a pre-existing neurological or psychiatric disease that would&#xD;
             confound the neurological or functional evaluations, mRS score at baseline must be ≤&#xD;
             1. This excludes patients who are severely demented, require constant assistance in a&#xD;
             nursing home type setting or who live at home but are not fully independent in&#xD;
             activities of daily living (toileting, dressing, eating, cooking and preparing meals,&#xD;
             etc.)&#xD;
&#xD;
          -  15. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor&#xD;
             from overseas).&#xD;
&#xD;
        Neuroimaging criteria:&#xD;
&#xD;
          -  16. Hypodensity on CT or restricted diffusion amounting to an ASPECTS score of &lt;7 on&#xD;
             NCCT or &lt;6 on DWI MRI. Patients 81 to 85 years old with ASPECTS score on non-contrast&#xD;
             CT or DWI MRI &lt;9 must be excluded. ASPECTS must be evaluated by CBV maps of CT&#xD;
             Perfusion, CTA source imaging (CTA-SI) or DWI-MR in patients whose vascular occlusion&#xD;
             study (CTA/MRA) confirming qualifying occlusion, is performed beyond 4.5 hours of last&#xD;
             seen well.&#xD;
&#xD;
          -  17. CT or MR evidence of hemorrhage (the presence of microbleeds is allowed).&#xD;
&#xD;
          -  18. Significant mass effect with midline shift.&#xD;
&#xD;
          -  19. Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial&#xD;
             dissection in the extracranial or petrous segment of the internal carotid artery that&#xD;
             cannot be treated or will prevent access to the intracranial clot or excessive&#xD;
             tortuosity of cervical vessels precluding device delivery/deployment&#xD;
&#xD;
          -  20. Subjects with occlusions in multiple vascular territories (e.g., bilateral&#xD;
             anterior circulation, or anterior/posterior circulation)&#xD;
&#xD;
          -  21. Evidence of intracranial tumor (except small meningioma).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Dávalos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Germans Trias i Pujol, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tudor Jovin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UPMC Stroke Institute, Pittsburgh, PA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel Chamorro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic Barcelona, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Serena, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Josep Trueta, Girona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex Rovira, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Vall D'Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria A De Miquel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Bellvitge, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Sanromán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Cobo, MD</last_name>
    <role>Study Director</role>
    <affiliation>UPC, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Molina, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Vall D'Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://fundacioictus.com/</url>
    <description>Fundacio Ictus is a non-profit organization sponsoring REVASCAT study</description>
  </link>
  <reference>
    <citation>Molina CA, Chamorro A, Rovira À, de Miquel A, Serena J, Roman LS, Jovin TG, Davalos A, Cobo E. REVASCAT: a randomized trial of revascularization with SOLITAIRE FR device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset. Int J Stroke. 2015 Jun;10(4):619-26. doi: 10.1111/ijs.12157. Epub 2013 Nov 10.</citation>
    <PMID>24206399</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 20, 2012</study_first_submitted>
  <study_first_submitted_qc>September 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>endovascular treatment</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

